RxDoctor Payments Data

Jane Lee

Acute Care · Mission Hills, CANPI 1245741552

Payments from drug & device makers

$3,624in general payments, 2019–2025

Across 214 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$367
  • Zimmer Biomet$264
  • Pfizer$262
  • Sanofi$223
  • Gilead$202
  • plus $954 from 10 others

What the payments were for

  • Travel & lodging$1444%
  • Food & beverage$3,48096%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,624 in reported general payments places this provider in the 90th percentile of 1,153 acute care providers in California.

See all acute care providers in California

Medicare billing

Part B allowed, 2024
$11,174
Medicare patients
71
Services billed
128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase14$45,041
LinzessLinaclotide36$31,104
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates45$2,612
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl153$2,200
Ursodiol11$1,772
Lactulose33$1,523
Sucralfate18$1,298
Omeprazole138$1,290
Pantoprazole Sodium118$1,157
Lubiprostone18$1,113
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl55$844
Colestipol Hcl20$816
Famotidine71$751
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl17$257
Hydrocortisone15$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,354$76,14550 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,153 acute care providers in California.

Other acute care in Mission Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →